REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

Adi Diab, Sandra P. D’Angelo, Mary Tagliaferri et al.|Annals of Oncology|2018

Cited by 7